Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $1,032,750.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marion Mccourt also recently made the following trade(s):

• On Thursday, September 3rd, Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $857.39, for a total value of $969,708.09.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $8.56 during trading hours on Thursday, hitting $843.47. The company had a trading volume of 496,170 shares, compared to its average volume of 839,664. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $729.93 and a 200-day simple moving average of $719.06. The firm has a market cap of $86.84 billion, a P/E ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 0.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.81 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Analyst Upgrades and Downgrades

REGN has been the topic of several analyst reports. Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Canaccord Genuity Group cut their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Fourteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $800.36.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported completion of a Phase 1/2 study evaluating its cemiplimab (Libtayo) combination with SNS-101. The update advances a potential oncology program, although no new efficacy results were disclosed. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: A market report projects continued growth in the global complement-inhibitors market through 2035 and lists Regeneron among the major industry participants, supporting the company’s longer-term opportunity but offering no company-specific financial update. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Analysts remain moderately optimistic about REGN’s outlook, with coverage highlighting its recent outperformance versus the broader healthcare sector. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Negative Sentiment: Multiple law firms are publicizing a securities class action focused on Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. The lawsuit alleges that the company’s disclosures about slowing event accrual and the trial protocol understated the risk of failing the primary endpoint; the trial ultimately failed, undermining earlier positive trial-risk messaging. Investors who purchased shares during the alleged class period may seek lead-plaintiff status by September 14, 2026. Hagens Berman Regeneron Securities Fraud Class Action Alert
• Negative Sentiment: The repeated litigation announcements increase headline, financial and reputational risk for Regeneron Pharmaceuticals (REGN). The core concern is that the failed melanoma study could delay or reduce expectations for a key growth opportunity and expose the company to potential damages and legal costs. REGN Investors Securities Fraud Lawsuit Notice

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the stock. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Finally, Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.